The Fulvestrant Injection, cataloged under National Stock Number 6505-01-666-4009, is classified within Federal Supply Class 6505 (Drugs and Biologicals) of the Medical, Dental, and Veterinary Equipment group. The manufacturer of record is Astrazeneca Pharmaceuticals Lp. The record lists 1 manufacturer part number for this item, enabling identification through both NSN and commercial part number lookups. 3 additional reference documents (drawings, advisory and superseded references) are recorded in the U.S. Government catalog. Current acquisition status: Active. Unit of issue: PG.
| Parameter | Value |
|---|---|
| NSN | 6505-01-666-4009 |
| Primary Part Number | NDC00310-0720-10 |
| Item Name | Fulvestrant Injection |
| FSC / FSG | 6505 / 65 — Drugs and Biologicals |
| Manufacturer | Astrazeneca Pharmaceuticals Lp |
| Status | ACTIVE |
| Acquisition Status | ACTIVE |
| DEMIL Code | DEMIL A — No Demilitarization Required |
| Hazard | Possible hazard — SDS may be required (DLA HMIC P) |
| Criticality Code | X |
| Unit of Issue | PG |
| Part Number | Manufacturer |
|---|---|
| NDC00310-0720-10 PRIMARY | Astrazeneca Pharmaceuticals Lp (USA) |
| Reference | Meaning |
|---|---|
| 6505NCM173720 | 5/1 Secondary reference Defense Medical Standardization Board |
| FASLODEX | 5/1 Secondary reference Astrazeneca Pharmaceuticals Lp |
| 1484575 | 5/1 Secondary reference U.S. Government activity |
NSN 6505-01-666-4009 is a Fulvestrant Injection, manufactured by Astrazeneca Pharmaceuticals Lp, classified under FSC 6505, Drugs and Biologicals. Status: active.
NSN 6505-01-666-4009 has 1 manufacturer part number on file: NDC00310-0720-10 (Astrazeneca Pharmaceuticals Lp).
Key specifications for NDC00310-0720-10: Special Features: FULVESTRANT INJECTION: 250 MG OF ACTIVE INGREDIENT PER 5 ML, (50 MG/ML), 2 PRE FILLED GLASS SYRINGES; FOR IM ADMINISTRATION; SINGLE PATIENT USE; BOTH SYRINGES MUST BE USED TO RECEIVE THE 500 MG DOSE; REQUIRES REFRIG BTWN 2-8 DEGREES C; DO NOT FREEZE; PROTECT FROM LIGHT; STORE IN THE ORIGINAL CARTON UNTIL TIME OF USE; HAZARDOUS CONTAINS ETHYL ALCOHOL AND BENZYL ALCOHOL; USED FOR THE TREATMENT OF HORMONE RECEPTOR POSITIVE METASTATIC BREAST CANCER IN POSTMENOPAUSAL WOMEN WITH DISEASE PROGRESSION FOLLOWING ANTI-ESTROGEN THERAPY; Part Name Assigned by Controlling Agency: FULVESTRANT INJECTION 250 MG PER 5 ML (50 MG/ML), 2 PRE-FILLED SYRINGES. 0 specifications are documented in the U.S. Government catalog.
Possible hazard — SDS may be required (DLA HMIC P). Hazard information on this page is shown exactly as it appears in the DLA record.
U.S. Government catalog: edition PUBLOGDVD v12.0.0 (OCT 2026), edition date 2026-10-01, retrieved 2026-10-16.
U.S. Government catalog: edition PUBLOGDVD v12.0.0 (OCT 2026), edition date 2026-10-01, retrieved 2026-10-18.